151 related articles for article (PubMed ID: 34482695)
1. [
Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
[TBL] [Abstract][Full Text] [Related]
2. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
Simon M; Mesmar F; Helguero L; Williams C
PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
Cho YS; Kang Y; Kim K; Cha YJ; Cho HS
Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156
[TBL] [Abstract][Full Text] [Related]
6. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
[TBL] [Abstract][Full Text] [Related]
7. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
9. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
10. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
11. Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
Lee IH; Lee SJ; Kang B; Lee J; Jung JH; Park HY; Park JY; Park NJ; Kim EA; Kang J; Chae YS
Breast Cancer Res Treat; 2024 May; 205(1):181-191. PubMed ID: 38279017
[TBL] [Abstract][Full Text] [Related]
12. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive
Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
[TBL] [Abstract][Full Text] [Related]
14. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
[TBL] [Abstract][Full Text] [Related]
16. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
[TBL] [Abstract][Full Text] [Related]
17. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a Fluorine-18 (
Altine B; Gai Y; Han N; Jiang Y; Ji H; Fang H; Niyonkuru A; Bakari KH; Rajab Arnous MM; Liu Q; Zhang Y; Lan X
Mol Pharm; 2019 Nov; 16(11):4563-4571. PubMed ID: 31553879
[TBL] [Abstract][Full Text] [Related]
19. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
Speers C; Zhao SG; Kothari V; Santola A; Liu M; Wilder-Romans K; Evans J; Batra N; Bartelink H; Hayes DF; Lawrence TS; Brown PH; Pierce LJ; Feng FY
Clin Cancer Res; 2016 Dec; 22(23):5864-5875. PubMed ID: 27225691
[TBL] [Abstract][Full Text] [Related]
20. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer.
Xie X; Chauhan GB; Edupuganti R; Kogawa T; Park J; Tacam M; Tan AW; Mughees M; Vidhu F; Liu DD; Taliaferro JM; Pitner MK; Browning LS; Lee JH; Shen Y; Wang J; Ueno NT; Krishnamurthy S; Hortobagyi GN; Tripathy D; Van Laere SJ; Bartholomeusz G; Dalby KN; Bartholomeusz C
Cancer Res Commun; 2023 Jun; 3(6):1078-1092. PubMed ID: 37377604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
